IPH: IP Services Leader - Patent Recovery Play with Network Effects
IPH trades at $4.78 vs fair value $9.29 (94% upside). Market leader with 29.3% Australian share, CIPO recovery catalyst, 32% EBITDA margin target.
View noteIPH trades at $4.78 vs fair value $9.29 (94% upside). Market leader with 29.3% Australian share, CIPO recovery catalyst, 32% EBITDA margin target.
View noteFair value $0.30 vs current $1.37 implies 78% downside risk. Monopolistic MRI-compatible cardiac ablation technology with FDA approval catalyst, but extreme 195x revenue valuation creates unfavourable risk-reward profile.
View noteMining technology leader trading at 44% premium to $2.36 fair value. Strong 29.3% EBITDA margins, 490+ patents, but execution risks from three simultaneous acquisitions amid uncertain exploration recovery.
View noteIVE Group trades at $2.99 vs fair value $8.19, offering 174% upside through portfolio transformation from print to packaging/logistics. Market leader with strong execution track record.
View noteAustralia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.
View noteHOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.
View noteHOLD rating with $1.47 fair value vs $1.757 current price. Exceptional 76% EBITDA margins offset by defensive positioning headwinds and succession risk.
View noteHOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.
View noteHOLD rating with $3.61 fair value vs $4.27 current price. Exceptional ROIC 71.6% offset by cyclical peak timing concerns and inevitable margin compression.
View noteTrading at $35.89 vs fair value $18.38 (95% premium). Development margins at 47.8% face compression to 42%. ROIC 8.2% trails WACC 9.6%. Quality business, extreme valuation.
View noteTrading at $2.94 vs $6.91 fair value (135% upside). Strong balance sheet, 48% recurring revenue, 23.1% ROIC. Cyclical normalisation expected.
View noteFreightways trades at NZ$10.22 versus NZ$20.85 fair value (104% upside). Market-leading logistics provider with 19.8% EBITDA margins, 14.2% ROIC, and demonstrated pricing power trading at 47% discount to peers.
View note